Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Finished Goods (2023 - 2025)

Cytosorbents (CTSO) has disclosed Finished Goods for 3 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Finished Goods changed N/A year-over-year to $2.3 million, compared with a TTM value of $2.3 million through Sep 2025, changed N/A, and an annual FY2024 reading of $1.7 million, down 10.33% over the prior year.
  • Finished Goods was $2.3 million for Q3 2025 at Cytosorbents, down from $2.4 million in the prior quarter.
  • Across five years, Finished Goods topped out at $2.4 million in Q2 2025 and bottomed at $1.7 million in Q4 2024.
  • Average Finished Goods over 3 years is $2.0 million, with a median of $1.9 million recorded in 2023.
  • Peak annual rise in Finished Goods hit 10.33% in 2024, while the deepest fall reached 10.33% in 2024.
  • Year by year, Finished Goods stood at $1.9 million in 2023, then decreased by 10.33% to $1.7 million in 2024, then soared by 38.98% to $2.3 million in 2025.
  • Business Quant data shows Finished Goods for CTSO at $2.3 million in Q3 2025, $2.4 million in Q2 2025, and $1.9 million in Q1 2025.